RADIOPHARM THERANOSTICS LTD Share Price Today: Live Updates & Key Insights

RADIOPHARM THERANOSTICS LTD share price today is $4.91, up 1.59%. The stock opened at $4.46 against the previous close of $4.72, with an intraday high of $4.94 and low of $4.45.

RADIOPHARM THERANOSTICS LTD Share Price Chart

RADIOPHARM THERANOSTICS LTD

us-stock
To Invest in {{usstockname}}
us-stock

RADIOPHARM THERANOSTICS LTD Share Price Performance

$4.91 0.0159(1.59%) RADX at 23 Mar 2026 02:57 PM Biotechnology
Lowest Today 4.45
Highest Today 4.94
Today’s Open 4.46
Prev. Close 4.72
52 Week High 10.63
52 Week Low 3.50
Day’s Range: Low 4.45 High 4.94
52-Week Range: Low 3.50 High 10.63
1 day return -
1 Week return -2.83
1 month return -3.23
3 month return -8.06
6 month return -18.25
1 year return -15.96
3 year return -
5 year return -
10 year return -

RADIOPHARM THERANOSTICS LTD Institutional Holdings

RADIOPHARM THERANOSTICS LTD Market Status

RADIOPHARM THERANOSTICS LTD Fundamentals

Market Cap 37.80 M

PB Ratio 1.2219

PE Ratio 0.0

Enterprise Value 12.78 M

Total Assets 86.48 M

Volume 43203

RADIOPHARM THERANOSTICS LTD Company Financials

About RADIOPHARM THERANOSTICS LTD & investment objective

Company Information Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Organisation Biotechnology

Employees 14

Industry Biotechnology

CEO Mr. Riccardo Canevari

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

RADIOPHARM THERANOSTICS LTD FAQs

What is the share price of RADIOPHARM THERANOSTICS LTD today?

The current share price of RADIOPHARM THERANOSTICS LTD is $4.91.

Can I buy RADIOPHARM THERANOSTICS LTD shares in India?

Yes, Indian investors can buy RADIOPHARM THERANOSTICS LTD shares by opening an international trading and demat account with Motilal Oswal.

How to buy RADIOPHARM THERANOSTICS LTD shares in India?

You can easily invest in RADIOPHARM THERANOSTICS LTD shares from India by:

Can I buy fractional shares of RADIOPHARM THERANOSTICS LTD?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of RADIOPHARM THERANOSTICS LTD?

RADIOPHARM THERANOSTICS LTD has a market cap of $37.80 M.

In which sector does RADIOPHARM THERANOSTICS LTD belong?

RADIOPHARM THERANOSTICS LTD operates in the Biotechnology sector.

What documents are required to invest in RADIOPHARM THERANOSTICS LTD stocks?

To invest, you typically need:

What is the PE and PB ratio of RADIOPHARM THERANOSTICS LTD?

The PE ratio of RADIOPHARM THERANOSTICS LTD is N/A and the PB ratio is 1.22.